CM
JUNO

Crestline Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Crestline Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7,631,631
Closed -$349M – 270
2017
Q4 		$349M Sell
7,631,631
-1,717,168
-18% -$85.7M 35.74% 1
2017
Q3 		$419M Sell
9,348,799
-8,033,393
-46% -$274M 58.3% 1
2017
Q2 		$520M Buy
17,382,192
+33,393
+0.2% +$824K 69.6% 1
2017
Q1 		$385M Hold
17,348,799
– – 70.45% 1
2016
Q4 		$327M Hold
17,348,799
– – 81.61% 1
2016
Q3 		$521M Hold
17,348,799
– – 66.02% 1
2016
Q2 		$667M Hold
17,348,799
– – 100% 1
2016
Q1 		$654M Sell
17,348,799
-8,600,000
-33% -$300M 100% 1
2015
Q4 		$1.13B Hold
25,948,799
– – 100% 1
2015
Q3 		$1.06B Sell
25,948,799
-40,000
-0.2% -$1.75M 100% 1
2015
Q2 		$1.39B Sell
25,988,799
-1,095,726
-4% -$58.2M 100% 1
2015
Q1 		$1.64B Hold
27,084,525
– – 100% 1
2014
Q4 		$1.41B Buy
+27,084,525
New +$1.21B 100% 1

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Crestline Management's JUNO Position: Q1 2018 in Review

Crestline Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 7,631,631 shares — an estimated $349M sold.

Crestline Management first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $1.64B in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Crestline Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Crestline Management sold 7,631,631 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $349M.
  • Crestline Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Crestline Management's Juno Therapeutics, Inc. position peaked at $1.64B in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Crestline Management's 13F filing for Q1 2018, filed 15 May 2018.